Pulmonary stenosis accounts for approximately 8% of all congenital heart defects, with clinical presentations varying from critical stenosis in newborns to asymptomatic mild stenosis.
This review provides an update on the diagnosis and therapeutic options for pulmonary stenosis, highlighting the need for better defined strategies in asymptomatic patients.
Pulmonary stenosis (PS) accounts for approximately 8% of all congenital heart defects. 1 Valvular PS is an isolated defect, but it can be associated other congenital heart defects, such as atrial defect (ASD), ventricular septal defect (VSD), and persistent ductus arteriosus. Combined and infundibular PS can be part of tetralogy Fallot (ToF). clinical presentation of PS may vary from stenosis in the newborn, to asymptomatic stenosis without need for therapy throughout. The need for treatment of critical PS in the is obvious, but the optimal timing, type treatment, and follow-up strategy for the asymptomatic is less well defined.
Cuypers et al. (2013) conducted a review in Pulmonary stenosis. Pulmonary stenosis accounts for approximately 8% of all congenital heart defects, with clinical presentations varying from critical stenosis in newborns to asymptomatic mild stenosis.